PamelaNewMD

Neurology • Hallettsville, TX

Neurooncology

Director of Neuro-Oncology, Methodist Neurological Institute

Join to view full profile

Dr. New is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. New's full profile

Already have an account?

Office
2248 County Road 387
Hallettsville, TX 77964
Phone+1 713-819-5268

Fax+1 713-790-2609

Education & Training

University of Texas Health Science Center at HoustonResidency, Neurology, 1985 - 1987
University of Texas M D Anderson Cancer CenterFellowship, Neuro-Oncology, 1985 - 1987
New York Presbyterian Hospital (Cornell Campus)Residency, Neurological Surgery, 1981 - 1984
New York Presbyterian Hospital (Cornell Campus)Residency, Surgery, 1981 - 1981
Baylor College of MedicineResidency, Internal Medicine, 1976 - 1979
Northwestern University The Feinberg School of MedicineClass of 1976

Certifications & Licensure

TX State Medical License 1985 - 2026
GA State Medical License 2017 - 2021
IN State Medical License 2019 - 2021
IL State Medical License 1980 - 1987
American Board of Psychiatry and NeurologyNeuro-Oncology

Clinical Trials

COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors Start of enrollment: 2000 Jul 01
Completed
Phase 1, Phase 2
Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma Start of enrollment: 2000 Jul 01
Completed
Phase 1, Phase 2
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Start of enrollment: 2006 Dec 01
Active, not recruiting
Phase 3
Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma Start of enrollment: 2005 Mar 01
Withdrawn
Not Applicable
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Start of enrollment: 2009 Jun 01
Completed
Phase 3
A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma Start of enrollment: 2010 Jul 01
Completed
Phase 1
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2011 Nov 01
Completed
Phase 3
Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors Start of enrollment: 2007 Mar 01
Withdrawn
Phase 2
Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma Start of enrollment: 2014 May 01
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

Solitary Leptomeningeal Recurrence From Prostate Adenocarcinoma After Treatment With Cytotoxic Gene Therapy, Radiation Therapy, and Androgen Deprivation Therapy.
Neil Chevli, Amarinthia E. Curtis, Suzanne Zein-Eldin Powell, Pamela New, E. Brian Butler
Advances in Radiation Oncology. 2021-05-09
9 citations
Correction: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma [J Transl Med., 16, (...
Linda M. Liau, Keyoumars Ashkan, David Tran, Jian Campian, John E. Trusheim
Journal of Translational Medicine. 2018-06-29
573 citations
HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial
Nabil Ahmed, Vita S. Brawley, Meenakshi Hegde, Kevin Bielamowicz, Mamta Kalra
JAMA Oncology. 2017-08-01

Professional Memberships

American Academy of Neurology - AAN
Member